论文部分内容阅读
Dendritoma即体外制备患者脑胶质瘤细胞与自身树突状细胞(dendritic cell,DC)融合的细胞,然后通过体内外实验证实Dendritoma的抗瘤效应,为脑胶质瘤的治疗开辟一条新途径,以提高脑胶质瘤患者的生存期及生存质量。近年来,随着免疫学、生物化学、分子生物学及生物技术的发展,Dendritoma细胞疫苗治疗脑胶质瘤在国内、外有很多医院都已进入临床试验阶段,而且已取得很好的疗效。本文主要对Dendrit-oma抗脑胶质瘤机制及在胶质瘤治疗中的应用做一综述。
Dendritoma is a method of in vitro preparation of cells fused with dendritic cells (DCs) of glioma cells in vivo. Dendritoma is proved to be an anti-tumor effect in vitro and in vivo, which opens up a new way for the treatment of glioma. To improve the survival of glioma patients and quality of life. In recent years, with the development of immunology, biochemistry, molecular biology and biotechnology, the treatment of glioma with Dendritoma cell vaccine has entered clinical trials at home and abroad, and has achieved good results. This article mainly reviews the mechanism of Dendrit-oma against glioma and its application in the treatment of glioma.